Age-Related Macular Degeneration
Conditions
Interventions
Eylea(aflibercept )
Sponsors
Department of Ophthalmology, Fukushima Medical University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)BCVA:0.1-0.5 2)AMD with subfoveal fluid on fluorescein angiography, indocyanine green angiography, and/or optical coherence tomography 3)Patients with willingness to provide written informed consent 4)Outpatients
Exclusion criteria
Exclusion criteria: 1)The greatest linear dimension (GLD)>12 Macular Photocoagulation Study Disc Areas 2)Presence of subretinal hemorrhage, scar or macular fibrosis(>50% lesion area) 3)Prior treatment with anti-VEGF drugs, photodynamic therapy 4)Prior treatment with dexamethasone(within 6 months) or triamcinolone (within 30 days), intraocular surgery(within 3 months 5)Active intraocular inflammation 6)Hypersensitivity or allergy to fluoresceinor or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products 7)Patients who the doctor in charge judges are ineligible for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of maintained visual acuity at month 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of best-corrected visual acuity (BCVA) and central retinal thickness. Proportion of subretinal fluid and regression ofpolypoidal lesion. | — |
Countries
Japan
Contacts
Public ContactMasaaki Saito
Fukushima Medical University School of Medicine Ophthalmology
Outcome results
None listed